HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Friday, AnalystRatings.com reports. The brokerage currently has a $29.00 price target on the stock.
“Valuation and impediments to achieving price target. We reiterate our Buy rating and are adjusting our price target to $29 from $31 based on the following factors: (1) adjustment to base year (positive effect); and (2) adjustment to fully diluted share count, taking into account the recent equity financing. The primary contributor to our valuation is tipifarninb (93.9%). Of tipifarnib’s contribution, 46.7% comes from the lead opportunity in HNSCC, with the remainder coming from the other indications currently being pursued (i.e., and CMML).”,” HC Wainwright’s analyst commented.
Other research analysts have also issued reports about the company. Citigroup upped their target price on Kura Oncology from $18.00 to $25.00 and gave the company a buy rating in a research report on Friday, May 24th. BidaskClub lowered Kura Oncology from a buy rating to a hold rating in a research report on Tuesday, July 23rd. Wedbush set a $30.00 target price on Kura Oncology and gave the company a positive rating in a research report on Monday, June 17th. Deutsche Bank initiated coverage on Kura Oncology in a research report on Thursday, July 18th. They set a buy rating and a $28.00 target price on the stock. Finally, Cowen reaffirmed a buy rating on shares of Kura Oncology in a research report on Monday, June 17th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Kura Oncology presently has an average rating of Buy and an average target price of $28.00.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 1st. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. Research analysts expect that Kura Oncology will post -1.69 EPS for the current fiscal year.
In other news, insider Antonio Gualberto sold 18,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total value of $379,980.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 11.00% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc grew its holdings in Kura Oncology by 21.7% during the fourth quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock worth $73,000 after acquiring an additional 923 shares during the period. Meeder Asset Management Inc. grew its holdings in Kura Oncology by 164.9% during the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock worth $38,000 after acquiring an additional 1,204 shares during the period. CWM LLC acquired a new stake in Kura Oncology during the first quarter worth about $25,000. DekaBank Deutsche Girozentrale grew its holdings in Kura Oncology by 22.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock worth $235,000 after acquiring an additional 2,200 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock worth $56,000 after acquiring an additional 2,420 shares during the period. 83.82% of the stock is currently owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: What are municipal bonds?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.